Drugs / GC021109
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02386306 | Feb → Oct 2015 | Alzheimer disease | GliaCure, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02254369 | Sep → Dec 2014 | — | GliaCure, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC021109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02254369 ↗ |
| Route | Oral | “single oral doses of GC021109” NCT02254369 ↗ |